Potential cognitive actions of (N-propargly-(3R)-aminoindan-5-yl)-ethyl, methyl carbamate (TV3326), a novel neuroprotective agent, as assessed in old rhesus monkeys in their performance of versions of a delayed matching task

Neuroscience

Volumn 119, Issue 3, 2003, Pages 669-678

  Buccafusco, J J ^a,b   Terry Jr , A V ^a,b   Goren, T ^c   Blaugrun, E ^c  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c TEVA PHARMACEUTICALS   (Israel)

Author keywords

Attention; Cholinesterase inhibitor; Delayed response task; MAO inhibitor; Memory; Operant task

Indexed keywords

(N PROPARGYLAMINOINDAN 5 YL)ETHYLMETHYLCARBAMATE; AMINE OXIDASE (FLAVIN CONTAINING); LADOSTIGIL; NEUROPROTECTIVE AGENT; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; ATTENTION; COGNITION; CONTROLLED STUDY; DRUG MECHANISM; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; STANDARD; TASK PERFORMANCE; TITRIMETRY; TREATMENT OUTCOME;

EID: 0037507200     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(02)00937-5     Document Type: Article

References (33)

1. Andringa G., Cools. The neuroprotective effects of CGP 3466B in the best in vivo model of Parkinson's disease, the bilaterally MPTP-treated rhesus monkey. J Neural Trans Suppl. 60:2000;215-225.
2. Arnsten A.F., Steere J.C., Hunt R.D. The contribution of α2-noradrenergic mechanisms of prefrontal cortical cognitive function potential significance for attention-deficit hyperactivity disorder . Arch Gen Psychiatry. 53:1996;448-455.
3. Bartus R.T. On neurodegenerative diseases, models, and treatment strategies lessons learned and lessons forgotten a generation following the cholinergic hypothesis . Exp Neurology. 163:2000;495-529.
4. Buccafusco J.J. Neuropharmacologic and behavioral actions of clonidine interactions with central neurotransmitters . Int Rev Neurobiol. 33:1992;55-107.
5. Buccafusco J.J., Jackson W.J., Terry A.V. Jr. Effects of concomitant cholinergic and adrenergic stimulation on learning and memory performance by primates. Life Sci. 51:1992;7-12.
6. Buccafusco J.J., Terry A.V. Jr. Multiple CNS targets for eliciting beneficial effects on memory and cognition. J Pharmacol Exp Ther. 295:2000;438-446.
7. Buccafusco J.J., Terry A.V. Jr, Murdoch P.B. A computer assisted cognitive test battery for aged monkeys. J Mol Neurosci. 19:2002;187-193.
8. Cai J.X., Arnsten A.F.T. Dose-dependent effects of the dopamine D1 receptor agonists A77636 or SKF81297 on spatial working memory in aged monkeys. J Pharmacol Exp Ther. 283:1997;183-189.
9. Francis P.T., Palmer A.M., Snape M., Wilcock G.K. The cholinergic hypothesis of Alzheimer's disease a review of progress . J Neurol Neurosurg Psychiatry. 66:1999;137-147.
10. Gelowitz D.L., Richardson J.S., Wishart T.B., Yu P.H., Lai C.T. Chronic L-deprenyl or L-amphetamine equal cognitive enhancement, unequal MAO inhibition . Pharmacol Biochem Behav. 47:1994;41-45.
11. Haroutunian V., Kanof P.D., Tsuboyama G., Davis K.L. Restoration of cholinomimetic activity by clonidine in cholinergic plus noradrenergic lesioned rats. Brain Res. 507:1990;261-266.
12. Irle E. Primate learning tasks reveal strong impairment in patients with presenile dementia of the Alzheimer type. Brain Cogn. 6:1987;429-449.
13. Jackson W.J., Buccafusco J.J. Clonidine enhances delayed matching-to-sample performance by young and aged monkeys. Pharmacol Biochem Behav. 39:1991;79-84.
14. Jacobsen J.S. Alzheimer's disease an overview of current and emerging therapeutic strategies . Curr Topics Med Chem. 2:2002;343-352.
15. Knoll J. (-)Deprenyl (Selegiline) past, present and future . Neurobiology (Budapest). 8:2000;179-199.
16. Kupsch A., Sautter J., Grotz M.E., Breithaupt W., Schwarz J., Youdim M.B., Riederer P., Gerlach M., Oertel W.H. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline. J Neural Trans. 108:2001;985-1009.
17. Mao Z.-M., Arnsten A.F.T., Li B.-M. Local infusion of an α-1 adrenergic agonist into the prefrontal cortex impairs spatial working memory performance in monkeys. Biol Psychiatry. 46:1999;1259-1265.
18. Maruyama W., Youdim M.B.H., Naof M. Antiapoptotic properties of rasagiline, N-proparglyamine-1(R)-aminoindan, and its optical (S)-isomer, TV1022. Ann NY Acad Sci. 939:2001;320-329.
19. DATATOP a multicenter controlled clinical trial in early Parkinson's disease . Arch Neurol. 46:1989;1052-1060.
20. Paule M.G., Bushnell P.J., Maurissen J.P.J., Wenger G.R., Buccafusco J.J., Chelonis J.J., Elliott R. Symposium overview the use of delayed matching-to-sample procedures in studies of short-term memory in animals and humans . Neurotoxicol Teratol. 20:1998;493-502.
21. Paule M.G. Validation of a behavioral test battery for monkeys. Buccafusco J.J. Methods of behavior analysis in neuroscience. 2001;281-294 CRC Press, New York.
22. Pratico D., Delanty N. Oxidative injury in diseases of the central nervous system focus on Alzheimer's disease . Am J Med. 109:2000;577-585.
23. Prendergast M.A., Jackson W.J., Terry A.V. Jr, Kille N.J., Arneric S.P., Buccafusco J.J. Age-related differences in distractibility and response to methylphenidate in monkeys . Cereb Cortex. 8:1998;164-172.
24. Prendergast M.A., Jackson W.J., Terry A.V., Decker M.W., Arneric S.A., Buccafusco J.J. Central nicotinic receptor agonists ABT-418, ABT-089, and (-)-nicotine reduce distractibility in young-adult monkeys. Psychopharmacology. 136:1998;50-58.
25. Robbins T., Everitt B. Arousal systems and attention. Gazzangia M. The cognitive neurosciences. 1995;703-720 MIT Press, Cambridge, MA.
26. Sano M., Ernesto C., Thomas R.G., Klauber M.R., Schafer K., Grundman M., Woodbury P., Growdon J., Cotman C.W., Pfeiffer E., Schneider L.S., Thal L.J. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease the Alzheimer's Disease Cooperative Study . N Engl J Med. 336:1997;1216-1222.
27. Shankaranarayana Rao B.S., Lakshamana M.K., Meti B.L., Raju T.R. Chronic (-)deprenyl administration alters dendritic morphology of layer III pyramidal neurons in the prefrontal cortex of adult Bonnett monkeys. Brain Res. 821:1999;218-223.
28. Taylor P. Anticholinesterase agents. Hardman J.G., Limbird L.E., Gilman A.G. Goodman and Gilman's pharmacological basis of therapeutics, 10th edition. 2001;175-191 McGraw-Hill, New York.
29. Taylor J.P., Hardy J., Fischbeck K.H. Toxic proteins in neurodegenerative disease. Science. 296:2002;1991-1995.
30. Terry A.V. Jr, Jackson W.J., Buccafusco J.J. Effects of concomitant cholinergic and adrenergic stimulation on learning and memory performance by young and aged monkeys. Cereb Cortex. 3:1993;304-312.
31. Weinstock M., Kirschbaum-Slager N., Lazarovici P., Bejar C., Youdim M.B.H., Shoham S. Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs. Ann NY Acad Sci. 939:2000;148-161.
32. Weinstock M., Bejar C., Wang R.H., Poltyrev T., Gross A., Finberg J.P., Youdin M.B. TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease. J Neural Trans Suppl. 60:2000;157-169.
33. Youdim M.B.H., Wadia A., Tatton W., Weinstock M. The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann NY Acad Sci. 939:2001;450-458.